Optimizing the standard of mental health care with clinically proven psilocybin treatments.
APEX is a patient-driven pharmaceutical company.
Our mission is to develop and commercialize clinically evaluated psilocybin-derived treatments to tackle the most critical unmet need in depression, anxiety, and PTSD among Veterans and the general public.
Our vision is to work with regulators and advocacy groups to expedite our clinical programs and data capture to facilitate broader global access.
Addressing a sub-optimal standard of care
“The drug effect of antidepressants is not clinically significant. If they are to be used at all, it should be as a last resort.”
– Dr. Irving Kirsch, Associate Director, Placebo Studies at the Harvard Medical School
Despite being the current standard of care treatment for depression, anxiety and PTSD, studies estimate antidepressants only improved symptoms in around 20% of people, marking substantial unmet need.